John Oyler

CEO John Oyler sells entire 3,410-share stake in BeOne (ONC) via 3 transactions for $933,592.21

John Oyler, Chief Executive Officer of BeOne Medicines Ltd., sold his entire remaining position in 3 separate transactions on 2026-06-23: 1,800 shares at $273.30, 1,290 shares at $274.12, and 320 shares at $275.10, totaling 3,410 shares for $933,592.21 at a blended average price of $273.78. Post-transaction holdings are zero, representing a complete exit from his equity stake. This occurs against a backdrop of stock weakness: the current price of $275.34 is -28.5% from the 52-week high of $385.22 and has declined -9.0% over 30 days. Notably, Oyler executed 5 prior sells at this ticker on 2026-06-08 and 2026-06-11 (outcomes not yet measurable), suggesting a deliberate multi-phase liquidation pattern within the past two weeks. His cross-ticker track record shows a 100.00% well-timed rate on 20 prior sells with an average 90-day return of -5.3%, though this cross-ticker history does not predict outcomes at ONC specifically, where prior measurable trade results are unavailable.

CEO John Oyler sells entire ONC holding: 3,693 shares for $980,686.49 across 3 trades on 2026-06-16

CEO John Oyler liquidated his complete stake in BeOne Medicines with 3 separate sales totaling 3,693 shares for $980,686.49 on June 16, 2026, executing the transactions at a blended average price of $265.55. The complete liquidation of 100.0% of holdings is a material departure from typical insider activity and occurs against a backdrop of recent multiple sell transactions at the same ticker (5 prior trades within the past week, all on or before June 11, 2026). While Oyler's cross-ticker track record shows a 100.00% well-timed rate on 20 prior sells with positive 30-day returns, same-ticker outcomes at ONC remain unmeasurable. The current price of $270.15 reflects the stock at -29.9% from its 52-week high of $385.22, suggesting the liquidation occurred in a declining market context.

CEO John Oyler sold 1,949 shares for $501,354.73 on 2026-06-11; retains 344,669 share options.

John Oyler, Chief Executive Officer, executed 4 separate sales totaling 1,949 shares for $501,354.73 at a blended average price of $257.24 on 2026-06-11. His pre-transaction non-derivative holdings of 1,949 shares were fully sold, though he retains 344,669 share options. Across his cross-ticker track record, his 20 prior sells averaged a 90-day return of -5.9%, with a 90d well-timed rate of 100.00%, while his 5 prior sells at ONC showed consistent 90-day declines (all well-timed at -3.7% to -4.8%). The current stock price of $268.20 is down 8.6% over 30 days and down 6.7% over 90 days from the transaction date, consistent with his historical pattern at this ticker. Against a macro backdrop of elevated valuation (P/E 766.29) and strong fundamentals (revenue growth +40.2% annually, net income $227,357,000.00), this open-market sale of non-derivative shares reflects the insider's persistent track record of selling before subsequent price weakness.

CEO John Oyler liquidates entire 4,940-share position at $270.56 average for $1.3M; stock down 15.2% in 30 days, 31.6% from high.

John Oyler, CEO of BeOne Medicines Ltd. (ONC), executed two separate sales totaling 4,940 shares for $1,336,547.58, completely liquidating his shareholding. The sales occurred at a blended average price of $270.56 on 2026-06-08. This total liquidation is notable given the stock's recent price deterioration: the current price of $263.61 represents a -15.2% decline over 30 days and a -31.6% drop from the 52-week high of $385.22. While the CEO's cross-ticker track record shows his prior sells achieved well-timed outcomes (90d well-timed rate of 100.00%), his five prior sales at ONC specifically (conducted on 2025-12-16) all exhibited 90-day declines ranging from -3.7% to -4.8%, suggesting a pattern of selling ahead of downward price moves at this ticker. The complete exit of holdings by the chief executive during a period of material stock weakness warrants close examination.

CEO John Oyler liquidates entire 100,000-share position in BeOne Medicines (ONC) across 24 sales totaling $30.7M over two days; stock down 18.9% from 52-week high

John Oyler, Chief Executive Officer of BeOne Medicines, executed 24 separate sales on December 15–16, 2025, liquidating his complete 100,000-share equity stake for a blended average price of $306.59. This total exit of his entire position—generating $30,659,418.84—occurs at a point where the stock is -18.9% from its 52-week high of $377.47 and has declined 18.7% over the past 30 days and 10.7% over 90 days. Notably, Oyler's prior five trades at ONC (all in September 2025) exhibited strong timing discipline: all five sells showed negative 90-day returns, meaning he sold before subsequent declines, with 90-day losses ranging from -4.2% to -5.2%. This complete exit by a sitting CEO—eliminating zero post-transaction holdings—represents a material signal that should be assessed against the company's operational metrics (revenue growth of +55.0% and quarterly net income of $124.8M) and the unusually elevated P/E ratio of 6121.00, which suggests the stock has disconnected significantly from earnings power.

CEO John Oyler liquidates entire 27.8K share position at BeOne Medicines for $9.1M (5 sales on 2025-09-16)

John Oyler, Chief Executive Officer of BeOne Medicines, completed a total liquidation of his equity stake through 5 separate sales totaling 27,803 shares for $9,055,693.88 on 2025-09-16, leaving him with zero post-transaction holdings. The blended average sale price of $325.71 compares to the current price of $342.89, placing the CEO's exit at a 4.7% discount to current levels and below the 52-week high of $351.13 by 2.4%. While his recent prior sales at ONC (5 trades in June-July 2025) each showed positive 30-day returns ranging from +12.7% to +14.2%, his cross-ticker track record across 20 prior sells shows an average 90-day return of +25.8% with a well-timed rate of 0.00%—meaning none of those prior sales preceded declines and all were followed by gains, indicating poorly-timed historical exits. The company remains fundamentally unprofitable on a full-year basis despite $1,315,300,000 in latest-quarter revenue and +55.0% annual revenue growth, which is material context for a complete insider divestiture by the CEO.

CEO John Oyler sold all 27,802 shares for $7,044,590.88 on 2025-07-09, exiting entire ONC position.

John Oyler, Chief Executive Officer of BeOne Medicines Ltd., executed 4 separate sales totaling 27,802 shares for $7,044,590.88 on 2025-07-09, reducing his holdings from 27,802 shares to 0 shares—a complete liquidation of his position. The blended average sale price of $253.38 compares to the current price of $250.30, meaning the stock has declined 4.6% over the prior 30 days (per PRICE section) since these transactions. At the same-ticker level, Oyler's prior 5 trades at ONC (all recent sales in June 2025) show only one measurable outcome: a 30-day return of -4.0% following his 2025-06-06 sale. The company reported $1.1B in latest-quarter revenue with +55.0% annual growth, yet remains unprofitable on a full-year basis, suggesting Oyler is liquidating a position amid company-specific execution or valuation concerns despite strong topline growth. A CEO's complete exit is material and warrants investor scrutiny into recent company developments.

CEO John Oyler sold all 3,174 shares (100% of holdings) at $261.57–$262.90 on 2025-06-23; 5 prior ONC sales in 6 days

CEO John Oyler completely exited his ONC position across 2 separate sales totaling 3,174 shares for $830,359.87, reducing his post-transaction holdings to zero. This full liquidation follows an aggressive selling sequence: 5 prior sales at the same ticker between 2025-06-06 and 2025-06-17, creating a pattern of sustained capital withdrawal over less than three weeks. The company's fundamentals show strong revenue growth of +55.0% year-over-year, but it remains unprofitable on a full-year basis despite recent quarterly profitability ($1.3M net income in the latest quarter on $1.1B revenue). The CEO's complete elimination of equity ownership, combined with the concentrated timing of these sales, removes his financial alignment with shareholder returns and warrants investor attention as a significant governance signal.

CEO John Oyler sold entire 5,140-share ONC stake in 2 transactions for $1,353,519.55 on 2025-06-16 and 2025-06-17, liquidating 100% of holdings.

John Oyler, Chief Executive Officer of BeOne Medicines, executed a complete liquidation of his shareholding through 2 separate sales totaling 5,140 shares for $1,353,519.55 across consecutive trading days (blended average price $263.33). The sales occurred at prices materially above the current market price of $252.78, though within the 52-week range. This represents a termination of his equity stake in the company he leads, which is highly unusual for an active CEO and raises questions about leadership continuity, confidence in future prospects, or signaling of internal developments. The company generated $1.1B in quarterly revenue with +55.0% annual revenue growth, but remains unprofitable on a full-year basis, which provides context for an equity holder potentially reassessing exposure. Complete executive liquidation warrants investor scrutiny of company communications and forward guidance.

CEO John Oyler sells entire 5,127-share stake (100.0%) in ONC for $1.3M at blended $252.77 avg

John Oyler, CEO of BeOne Medicines, executed 5 separate sales totaling 5,127 shares for $1,295,946.05 on 2025-06-06, completely liquidating his shareholding (net change: -100.0% vs pre-transaction holdings of 5,127 shares). The sales occurred across a narrow price band ($250.84–$255.74) at a blended average of $252.77, versus a current price of $263.42 (5.4% above the 52-week high of $278.38). The complete divestiture by the sitting CEO warrants investor attention, particularly given the company's full-year unprofitability despite 55.0% annual revenue growth and a $369.7B market cap, which suggests execution risk on the path to profitability. His cross-ticker track record shows 20 prior sells, but the material signal here is the total exit of his position immediately after a 13.6% 30-day price gain.